Cargando…
CaMKII inhibitor KN‐93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p‐VEGFR2 and STAT3 pathways
Persistent cardiac Ca(2+)/calmodulin‐dependent Kinase II (CaMKII) activation was considered to promote heart failure (HF) development, some studies believed that CaMKII was a target for therapy of HF. However, CaMKII was an important mediator for the ischaemia‐induced coronary angiogenesis, and new...
Autores principales: | Ni, Yajuan, Deng, Jie, Bai, Hongyuan, Liu, Chang, Liu, Xin, Wang, Xiaofang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743652/ https://www.ncbi.nlm.nih.gov/pubmed/34845819 http://dx.doi.org/10.1111/jcmm.17081 |
Ejemplares similares
-
CaMKII inhibition with KN93 attenuates endothelin and serotonin receptor-mediated vasoconstriction and prevents subarachnoid hemorrhage-induced deficits in sensorimotor function
por: Edvinsson, Lars, et al.
Publicado: (2014) -
Hypoxic stabilization of mRNA is HIF-independent but requires mtROS
por: Fortenbery, Grey W, et al.
Publicado: (2018) -
CaMKII: The molecular villain that aggravates cardiovascular disease
por: Zhang, Peiying
Publicado: (2017) -
Ageing Increases Cardiac Electrical Remodelling in Rats and Mice via NOX4/ROS/CaMKII-Mediated Calcium Signalling
por: Luo, Xian, et al.
Publicado: (2022) -
AT1R-Mediated Apoptosis of Bone Marrow Mesenchymal Stem Cells Is Associated with mtROS Production and mtDNA Reduction
por: Zhang, Fenxi, et al.
Publicado: (2019)